Open AccessThe role of nebivolol in the management of hypertensive patients: from pharmacological profile to treatment guidelines
Author(s) -
Claudio Ferri
Publication year - 2021
Publication title -
future cardiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.392
H-Index - 33
eISSN - 1744-8298
pISSN - 1479-6678
DOI - 10.2217/fca-2021-0048
Subject(s) - medicine , nebivolol , tolerability , cardiology , heart failure , atrial fibrillation , adrenergic beta antagonists , myocardial infarction , ivabradine , angina , intensive care medicine , heart rate , blood pressure , propranolol , adverse effect
According to the most recent international guidelines, β-blockers maintain a central role in the management of hypertension, being recommended at any treatment step when there is a specific indication, such as heart failure, angina, postacute myocardial infarction, atrial fibrillation or pregnancy. However, β-blockers are not a homogeneous class: individual molecules differ in terms of pharmacological and clinical profile and are therefore suitable for different patient subtypes. In particular nebivolol, a third generation β 1 -selective β-blocker with vasodilating properties, neutral metabolic effects and good tolerability, proved to have advantages over other β-blockers, which makes the drug suitable in a wide variety of hypertensive patients with or without comorbidities.